Post Reply
1-20 of 28
The MOST " sia suay" privatization in the recent history.
Joelton ( Date: 12-Sep-2025 11:13) Posted:
|
TalkMed to delist from SGX on Sep 15
Scheme consideration payments have been made to shareholders
[SINGAPORE] Healthcare provider TalkMed announced on Thursday (Sep 11) that it will be delisted from the Singapore Exchange from 9 am on Sep 15.
This follows confirmation from TW Troy Limited, a special-purpose vehicle managed by healthcare group Tamarind Health, that it had completed payment of the scheme consideration to TalkMed shareholders on Thursday.
TW Troy had earlier offered to privatise the mainboard-listed company via a scheme of arrangement at S$0.456 per share.
The proposed acquisition received clearance from the Competition and Consumer Commission of Singapore on Jun 27. TalkMed shareholders subsequently approved the scheme resolution at an extraordinary general meeting in July, with approximately 89.1 per cent of those present voting in favour of the privatisation offer.
Thanks. By the way, I accessed to my CDP portal, I noted that my holding has been blocked already meaning Talkmed has taken over my shares
spursfan ( Date: 03-Sep-2025 09:34) Posted:
|
Scheme of arrangement offer is thru shareholders giving approval at the Scheme meeting and thereafter get the court to grant the approval. Both approval already obtained. All notices were in electronic format on sgx and company website.
tccroy ( Date: 03-Sep-2025 08:46) Posted:
|
But I have not received letter for acceptance of offer at all
spursfan ( Date: 03-Sep-2025 08:42) Posted:
|
5. KEY EVENTS AND INDICATIVE DATES
Shareholders are reminded to note the following indicative timetable in relation to the Scheme:
Effective Date : 2 September 2025
Expected date for payment of the Scheme
Consideration : By 11 September 2025
Expected date for the delisting of the
Shares from the SGX-ST : By 15 September 2025
Shareholders are reminded to note the following indicative timetable in relation to the Scheme:
Effective Date : 2 September 2025
Expected date for payment of the Scheme
Consideration : By 11 September 2025
Expected date for the delisting of the
Shares from the SGX-ST : By 15 September 2025
tccroy ( Date: 03-Sep-2025 08:32) Posted:
|
When is the payout to all shareholders?
It is embarrassing low balled. Those major shareholders have short changed themselves as the share price could have easily recover back to 80cents.
tccroy ( Date: 02-Jul-2025 08:50) Posted:
|
https://sg.finance.yahoo.com/news/ai-energy-boom-3-singapore-093000866.html
Geo Energy is mentioned in this article
Geo Energy is mentioned in this article
Takeover at 45.6 cents is too low. I have been collecting dividends every year since their IPO in 2011. No need to consider selling to them.
Joelton ( Date: 28-Jun-2025 13:22) Posted:
|
Singapore has a great healthcare system. Lots of options.
CCCS okays Tamarind Health&rsquo s proposed acquisition of TalkMed
The watchdog says the proposed transaction will not substantially lessen competition within the Singapore market
[SINGAPORE] The Competition and Consumer Commission of Singapore (CCCS) has cleared Tamarind Health&rsquo s proposed acquisition of tertiary healthcare service provider TalkMed Group.
The competition watchdog, in a statement on Friday (Jun 27), said it assessed that the proposed transaction will not substantially lessen competition within the Singapore market.
TW Troy, a special purpose vehicle managed by Tamarind Health, proposed to privatise mainboard-listed TalkMed by way of scheme of arrangement at S$0.456 per share on Dec 23, 2024.
CCCS said it commenced its review on Jan 13, to see whether the proposed privatisation would infringe Section 54 of the Competition Act 2004, which prohibits mergers that may substantially lessen competition.
It conducted a public consultation from Jan 21 to 31, seeking feedback from stakeholders such as the involved parties&rsquo competitors and insurance service providers.
Based on its assessment of the parties&rsquo submissions and third-party feedback, CCCS concluded that the proposed transaction is unlikely to substantially lessen competition in Singapore, in relation to the supply of private medical oncology services.
Medical oncology refers to the field of medicine that deals with the treatment of cancer primarily with drugs, such as chemotherapy.
CCCS reasoned that patients can choose alternative providers of medical oncology services in both public and private sectors in Singapore, limiting the impact of the proposed merger.
Furthermore, it added that any increase in the parties&rsquo market power upon the proposed transaction would likely be constrained by insurers &ndash who play a &ldquo significant role&rdquo in affecting how patients select and finance private medical oncology services &ndash as well as the regulatory framework governing the healthcare sector in Singapore.
Tamarind Health is a pan-Asian oncology-focused group headquartered in Singapore. It is controlled by alternative asset manager Templewater and its affiliates.
As part of the deal, 65 Equity Partners, a Singapore-based global investment firm backed by Temasek, will subscribe for shares in Tamarind Health through its local enterprise fund.
After the transaction, 65 Equity Partners will hold about 18.3 per cent of the voting interest in Tamarind Health, while doctor shareholders will hold about 31.3 per cent.
Fund manager 65 Equity Partners&rsquo role in TalkMed privatisation offer is at odds with its core
With one of its funds&rsquo mandate to support companies eyeing an SGX listing, encouraging the medical group&rsquo s delisting through the other is a bad look
TALKMED Group late last year received a privatisation proposal from oncology-focused group Tamarind Health. But there was a curious player tagging along in the deal &ndash Singapore-based global investment firm 65 Equity Partners.
As part of the privatisation deal, the Temasek-backed investment company will subscribe for shares in Tamarind Health through its local enterprise fund, gaining 18.3 per cent of the voting interest in Tamarind Health.
The participation of 65 Equity Partners in this deal is baffling.
On the face of it, it appears that TalkMed&rsquo s privatisation and combination with Tamarind Health will spur growth for the medical group. It said that the bigger entity will be &ldquo better positioned to attract patients from the region seeking high-quality and competitive treatment&rdquo .
However, 65 Equity Partners has a mandate through its second fund, Anchor Fund @ 65 &ndash supporting high-quality businesses that are seeking a listing on the Singapore Exchange (SGX), according to its chief executive officer Tan Chong Lee.
Being involved in TalkMed&rsquo s privatisation, albeit through a different fund, appears to be at odds with this.
Strange moves
This is not the first time that 65 Equity Partners has left market watchers scratching their heads.
The investment firm in July 2024 pumped S$100 million, from the same local enterprise fund that it is using for TalkMed&rsquo s privatisation, into precision manufacturer Hi-P International.
This came less than four years after Hi-P was taken private by its founder Yao Hsiao Tung, in a deal valuing the company at S$1.6 billion.
Similarly, 65 Equity Partners in October 2022 invested S$150 million from its Anchor Fund @ 65 in exhibition provider Cityneon.
However, Cityneon had delisted in February 2019, when its then chairman Ron Tan and a Hong Kong investor made a privatisation offer of S$1.30 per share.
This column, too, previously questioned whether these companies were getting a second bite of the cherry through 65 Equity Partners&rsquo investments.
This new investment also comes against the backdrop of Singapore&rsquo s amped-up efforts to revive the ailing local equities market.
In 2024, delistings from SGX outpaced new entrants to the bourse, with 20 companies going private compared with four initial public offerings &ndash continuing the downward spiral of recent years.
The Monetary Authority of Singapore has established a review group to look into ways to enliven the local bourse. The review group involves parties from the private and public sectors &ndash including Temasek, which backs 65 Equity Partners.
It is thus difficult to understand the logic behind 65 Equity Partners joining in with privatising TalkMed, as it seems to be completely at odds with what the review group is trying to achieve.
Calling the mandate into question
Perhaps, 65 Equity Partners&rsquo involvement could help pave the way for TalkMed to eventually return to the Singapore bourse, if it ever decides to take another chance on the public markets.
Indeed, observers have said that the investments in Hi-P and Cityneon are moves to chart their paths back to SGX.
And, perhaps, TalkMed&rsquo s delisting is necessary &ndash for monetary reasons or because it requires an injection of funds &ndash to help Singapore become the regional champion it aspires to be.
But for a fund manager with at least one mandate to encourage companies to list here, the deal does not offer good optics for investors who are already cautious about Singapore equities.
So many low ball offer and is so embarrassing and yet the exchange has done nothing.
Sgvale ( Date: 26-Dec-2024 11:10) Posted:
|
Hope Raffles Medical will offer better.
Another low ball offer of this zombie stock exchange.
Joelton ( Date: 24-Dec-2024 09:10) Posted:
|
Anyone knows if we can still get the dividends that will be declared after their YE results?
TalkMed receives privatisation offer for S$0.456 per scheme share
The company says it provides shareholders with an opportunity to &lsquo realise their investment in the shares at a premium&rsquo
TERTIARY healthcare services provider TalkMed Group : 5G3 +4.6% on Monday (Dec 23) announced that it has received a privatisation proposal from TW Troy, a special purpose vehicle managed by Tamarind Health.
The offer by TW Troy is made by way of scheme of arrangement. It is offering S$0.456 in cash per scheme share. This represents a 20 per cent premium to the last traded price of S$0.38 on Apr 5.
It also represents a premium of about 22.6 per cent, 22.9 per cent, 21.6 per cent and 16.3 per cent over the volume weighted average price per share for the one-month, three-month, six-month and 12-month periods, respectively, up to Apr 5.
Apr 5 is the last undisturbed trading day for TalkMed as the company disclosed the following day that it received interest from parties considering a stake acquisition.
The offer price of S$0.456 a share is also 629.6 per cent higher than TalkMed&rsquo s net asset value per ordinary share of S$0.0625 as at Jun 30, according to the company&rsquo s last published financial statements.
TalkMed is a mainboard-listed company providing medical oncology, stem cell transplants and palliative care services. It has operations in Singapore and the region.
The company noted that the offer provides shareholders with an opportunity to &ldquo realise their investment in the shares at a premium&rdquo .
It added that the transaction also allows investors to exit their investment in a &ldquo low trading liquidity environment&rdquo , without incurring brokerage and other trading costs.
Wider range of services
The deal is expected to improve patient care as a wider range of services and expertise will be brought together under a single organisation, said TalkMed.
TalkMed will update shareholders in due course when it becomes aware of any material developments.
Discussions on stake sale still ongoing, says TalkMed
&ldquo The combined entity will be better positioned to attract patients from the region seeking high-quality and competitive treatment, strengthening Singapore&rsquo s role as a hub for medical tourism,&rdquo it added.
Ang Peng Tiam, TalkMed&rsquo s chief executive, said that the transaction will allow &ldquo collaboration within a bigger oncology network&rdquo .
&ldquo This means improved access to innovative treatments and a wider range of deep medical expertise,&rdquo he added.
Tamarind is a pan-Asian oncology-focused group headquartered in Singapore. It is controlled by alternative asset manager Templewater and its affiliates.
As part of the deal, 65 Equity Partners, a Singapore-based global investment firm backed by Temasek, will subscribe for shares in Tamarind Health through its local enterprise fund.
After the transaction, 65 Equity Partners will hold about 18.3 per cent of the voting interest in Tamarind Health, while doctor shareholders will hold about 31.3 per cent.
another privisation on the cheap